These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1128 related items for PubMed ID: 18708300

  • 1. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain.
    Vondrackova D, Leyendecker P, Meissner W, Hopp M, Szombati I, Hermanns K, Ruckes C, Weber S, Grothe B, Fleischer W, Reimer K.
    J Pain; 2008 Dec; 9(12):1144-54. PubMed ID: 18708300
    [Abstract] [Full Text] [Related]

  • 2. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation.
    Meissner W, Leyendecker P, Mueller-Lissner S, Nadstawek J, Hopp M, Ruckes C, Wirz S, Fleischer W, Reimer K.
    Eur J Pain; 2009 Jan; 13(1):56-64. PubMed ID: 18762438
    [Abstract] [Full Text] [Related]

  • 3. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study.
    Hermanns K, Junker U, Nolte T.
    Expert Opin Pharmacother; 2012 Feb; 13(3):299-311. PubMed ID: 22224497
    [Abstract] [Full Text] [Related]

  • 4. Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain.
    Clemens KE, Mikus G.
    Expert Opin Pharmacother; 2010 Feb; 11(2):297-310. PubMed ID: 20030568
    [Abstract] [Full Text] [Related]

  • 5. Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation.
    Gatti A, Casali M, Lazzari M, Tufaro G, Gafforio P, Silvestri C, Marcassa C, Sabato AF.
    Adv Ther; 2013 Jan; 30(1):41-59. PubMed ID: 23269562
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
    Hale ME, Dvergsten C, Gimbel J.
    J Pain; 2005 Jan; 6(1):21-8. PubMed ID: 15629415
    [Abstract] [Full Text] [Related]

  • 7. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial.
    Löwenstein O, Leyendecker P, Hopp M, Schutter U, Rogers PD, Uhl R, Bond S, Kremers W, Nichols T, Krain B, Reimer K.
    Expert Opin Pharmacother; 2009 Mar; 10(4):531-43. PubMed ID: 19243306
    [Abstract] [Full Text] [Related]

  • 8. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain.
    Simpson K, Leyendecker P, Hopp M, Müller-Lissner S, Löwenstein O, De Andrés J, Troy Ferrarons J, Bosse B, Krain B, Nichols T, Kremers W, Reimer K.
    Curr Med Res Opin; 2008 Dec; 24(12):3503-12. PubMed ID: 19032132
    [Abstract] [Full Text] [Related]

  • 9. A comparison of oxycodone prolonged-release vs. oxycodone + naloxone prolonged-release after laparoscopic hysterectomy.
    Comelon M, Wisloeff-Aase K, Raeder J, Draegni T, Undersrud H, Qvigstad E, Bjerkelund CE, Lenz H.
    Acta Anaesthesiol Scand; 2013 Apr; 57(4):509-17. PubMed ID: 23301686
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials.
    Löwenstein O, Leyendecker P, Lux EA, Blagden M, Simpson KH, Hopp M, Bosse B, Reimer K.
    BMC Clin Pharmacol; 2010 Sep 29; 10():12. PubMed ID: 20920236
    [Abstract] [Full Text] [Related]

  • 11. Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial.
    Baron R, Jansen JP, Binder A, Pombo-Suarez M, Kennes L, Müller M, Falke D, Steigerwald I.
    Pain Pract; 2016 Jun 29; 16(5):600-19. PubMed ID: 26554630
    [Abstract] [Full Text] [Related]

  • 12. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice.
    Schutter U, Grunert S, Meyer C, Schmidt T, Nolte T.
    Curr Med Res Opin; 2010 Jun 29; 26(6):1377-87. PubMed ID: 20380506
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis.
    Lazzari M, Greco MT, Marcassa C, Finocchi S, Caldarulo C, Corli O.
    Drug Des Devel Ther; 2015 Jun 29; 9():5863-72. PubMed ID: 26586937
    [Abstract] [Full Text] [Related]

  • 14. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR.
    Dupoiron D, Stachowiak A, Loewenstein O, Ellery A, Kremers W, Bosse B, Hopp M.
    Eur J Pain; 2017 Oct 29; 21(9):1528-1537. PubMed ID: 28641363
    [Abstract] [Full Text] [Related]

  • 15. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain.
    Sandner-Kiesling A, Leyendecker P, Hopp M, Tarau L, Lejcko J, Meissner W, Sevcik P, Hakl M, Hrib R, Uhl R, Dürr H, Reimer K.
    Int J Clin Pract; 2010 May 29; 64(6):763-74. PubMed ID: 20370845
    [Abstract] [Full Text] [Related]

  • 16. Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial.
    Leng X, Zhang F, Yao S, Weng X, Lu K, Chen G, Huang M, Huang Y, Zeng X, Hopp M, Lu G.
    Adv Ther; 2020 Mar 29; 37(3):1188-1202. PubMed ID: 32020565
    [Abstract] [Full Text] [Related]

  • 17. The attractiveness of opposites: agonists and antagonists.
    O'Brien T.
    J Pain Palliat Care Pharmacother; 2015 Mar 29; 29(1):67-9. PubMed ID: 25643224
    [Abstract] [Full Text] [Related]

  • 18. Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study.
    Dupoiron D, Stachowiak A, Loewenstein O, Ellery A, Kremers W, Bosse B, Hopp M.
    Eur J Pain; 2017 Oct 29; 21(9):1485-1494. PubMed ID: 28474460
    [Abstract] [Full Text] [Related]

  • 19. Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone.
    Morlion B, Clemens KE, Dunlop W.
    Clin Drug Investig; 2015 Jan 29; 35(1):1-11. PubMed ID: 25479959
    [Abstract] [Full Text] [Related]

  • 20. Combined oral prolonged-release oxycodone and naloxone in chronic pain management.
    Mercadante S, Giarratano A.
    Expert Opin Investig Drugs; 2013 Jan 29; 22(1):161-6. PubMed ID: 23215628
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.